Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1 (Cancelled).
- 2 (Previously Presented). An isolated protein which is capable of binding to tumor necrosis factor receptorassociated 2 protein (TRAF2), said protein comprising:
 - (A) a polypeptide of SEQ ID NO:3; or
- (B) a variant that has no more than ten amino acid changes from the amino acid sequence of SEQ ID NO:3, wherein said variant is capable of binding to TRAF2.
- 3 (Original). The isolated protein of claim 2, which is a protein comprising the amino acid sequence of SEQ ID NO:3.
 - 4-19 (Cancelled).
- 20 (Previously Presented). A composition comprising the isolated protein of claim 2 and a pharmaceutically acceptable excipient, diluent, or auxiliary agent.
- 21 (Previously Presented). A molecule having the binding portion of an antibody capable of binding to the portion of said isolated protein of claim 2 that is said polypeptide of (A) or said variant of (B).

- 22 (Original). The molecule of claim 21, which is an antibody.
- 23 (Original). The molecule of claim 22, wherein said antibody is a monoclonal antibody.
- 24 (Previously Presented). A composition comprising the molecule of claim 21, and a pharmaceutically acceptable excipient, diluent, or auxiliary agent.

25-37 (Cancelled).

38 (Previously Presented). An isolated protein in accordance with claim 2, wherein said protein and said variant are each capable of binding to a component of the NF-kB complex selected from the group consisting of IKappaB kinase complex associated protein (IKAP), IKappaB kinase-alpha (IKK-alpha), IKappaB kinase-beta (IKK-beta), IKappaB kinase-gamma (IKK-gamma) and NF-kB inducing kinase (NIK).

39-41 (Cancelled).

42 (Previously Presented). An isolated protein in accordance with claim 2, comprising a variant of the polypeptide of SEQ ID NO:3, which variant has no more than ten amino acid changes from the amino acid sequence of SEQ ID NO:3, and which variant is capable of binding to TRAF2.

43 (Cancelled).

44 (Previously Presented). A molecule having the binding portion of an antibody capable of binding to the polypeptide of SEQ ID NO:3.

45 (Previously Presented). The molecule of claim 44, which is an antibody.

46 (Previously Presented). The molecule of claim 45, wherein said antibody is a monoclonal antibody.

47 (Cancelled).

48 (Previously Presented). The isolated protein of claim 2, wherein said variant of (B) has no more than five amino acid changes from the amino acid sequence of SEQ ID NO:3.

49 (Previously Presented). The isolated protein of claim 2, wherein each said change from the amino acid sequence of SEQ ID NO:3 is a conservative substitution selected from among the substitutions in the following list:

Original

<u>Residue</u>	Substitution
Ala	Gly;Ser
Arg	Lys
Asn	Gln;His
Asp	Glu
Cys	Ser

Gln Asn

Glu Asp

Gly Ala; Pro

His Asn; Gln

Ile Leu; Val

Leu Ile; Val

Lys Arg; Gln; Glu

Met Leu; Tyr; Ile

Phe Met; Leu; Tyr

Ser Thr

Thr Ser

Trp Tyr

Tyr Trp; Phe

Val Ile; Leu

or a conservative substitution that is an exchange within one of the following five groups:

Small aliphatic, nonpolar or

slightly polar residues: Ala, Ser, Thr, Pro, Gly;

Polar negatively charged

residues and their amides: Asp, Asn, Glu, Gln;

Polar, positively charged residues: His, Arg, Lys;

Large aliphatic nonpolar residues: Met, Leu, Ile, Val, Cys; and

Large aromatic residues: Phe, Tyr, Trp.

50 (Previously Presented). The isolated protein of claim 49, wherein said variant has no more than 5 of said amino acid changes from the amino acid sequence of SEQ ID NO:3.

- 51 (New). An isolated protein comprising:
- A) a polypeptide of SEQ ID NO: 3; or
- B) a variant that has no more than 10 amino acid changes from the amino acid sequence of SEQ ID NO:3.
- 52 (New). The isolated protein of claim 51, wherein said variant has no more than 5 of said amino acid changes from the amino acid sequence of SEQ ID NO:3.